Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPIs with domperidone vs PPIs alone for GERD symptoms in scleroderma with non-erosive reflux disease
TCTR20240917007Phase 3Recruiting
- Sponsor
- Witsarut Manasirisuk
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of omeprazole and domperidone in gastroesophageal reflux disease (GERD) and systemic sclerosis (SSc) (2 arms), sponsored by Witsarut Manasirisuk. Started Jul 2024; status: recruiting.
02
Drugs
omeprazoledomperidone
03
Conditions
gastroesophageal reflux disease (GERD)systemic sclerosis (SSc)
Beyond the preview
Go deeper on TCTR20240917007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240917007.